All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias Emergency room visit or hospitalizationdetailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.12 [0.01; 2.35]
0.12 [0.01 ; 2.35 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1 0% 1,505 NA not evaluable deathsdetailed results BLAZE-2 US (Cohen), 2021 0.83 [0.25; 2.73]
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1.00 [0.14; 7.08]
0.87 [0.31 ; 2.41 ] BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2 0% 3,583 moderate not evaluable hospitalizationdetailed results PROVENT, 2022 0.04 [0.00; 0.63]
0.04 [0.00 ; 0.63 ] PROVENT, 2022 1 0% 4,685 NA not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.17 [0.09; 0.33]
PROVENT, 2022 0.23 [0.10; 0.54]
0.19 [0.12 ; 0.33 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021, PROVENT, 2022 2 0% 6,577 moderate not evaluable infection (PCR positive symptomatic or not)detailed results BLAZE-2 US (Cohen), 2021 0.43 [0.28; 0.67]
0.43 [0.28 ; 0.67 ] BLAZE-2 US (Cohen), 2021 1 0% 961 NA not evaluable severe COVID-19 occurrencedetailed results PROVENT, 2022 0.25 [0.01; 7.50]
0.25 [0.01 ; 7.50 ] PROVENT, 2022 1 0% 5,172 NA not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2.97 [1.75; 5.03]
2.97 [1.75 ; 5.03 ] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1 0% 2,617 NA not evaluable adverse eventsdetailed results BLAZE-2 US (Cohen), 2021 2.02 [1.54; 2.64]
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.62 [0.52; 0.74]
1.11 [0.35 ; 3.53 ] BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2 98% 3,792 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 08:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290